prednisone

• post-bronchodilator FEV1, percent predicted, pooled pre- vs post-treatment

  increases, significant mean increase (↑8.1%; 95% CI: 5.3-10.8; z = 5.8; p < 0.001), n = 194

  After 6-14 days of treatment, there was a significant mean increase in post-bronchodilator FEV1 (↑8.1%; 95% CI: 5.3-10.8; z = 5.8; p < 0.001; Figure 5).

  PMID:25410844 · one of two readings recorded this

• post-bronchodilator FEV1

  increases, significant mean increase (up 8.1%; 95% CI 5.3-10.8), n = 194

  After 6-14 days of treatment, there was a significant mean increase in post-bronchodilator FEV1 (↑8.1%; 95% CI: 5.3-10.8; z = 5.8; p < 0.001; Figure 5).

  PMID:25410844 · one of two readings recorded this

• sputum eosinophil cationic protein (ECP), µg/L, pooled pre- vs post-treatment

  decreases, five-fold mean reduction (↓267.6; 95% CI: 244.6-290.6; p < 0.001), n = 80

  In addition, among the studies evaluating ECP (in µg/L) in subjects receiving prednisone or prednisolone (n = 80), the treatment resulted in a five-fold mean reduction in ECP levels (↓267.6; 95% CI: 244.6-290.6; p < 0.001; Figure 4).

  PMID:25410844 · one of two readings recorded this

• sputum eosinophil cationic protein

  decreases, five-fold mean reduction (down 267.6 µg/L; 95% CI 244.6-290.6), n = 80

  In addition, among the studies evaluating ECP (in µg/L) in subjects receiving prednisone or prednisolone (n = 80), the treatment resulted in a five-fold mean reduction in ECP levels (↓267.6; 95% CI: 244.6-290.6; p < 0.001; Figure 4).

  PMID:25410844 · one of two readings recorded this

• sputum eosinophil count, percentage change pooled across pre- vs post-treatment observational and randomised studies of prednisone/prednisolone

  decreases, six-fold mean reduction (↓8.2%; 95% CI: 7.7-8.7; p < 0.001), n = 198

  Not recorded as a finding: this platform holds no node for the endpoint

  The pooled analysis (n = 198) showed a six-fold mean reduction in the number of sputum eosinophils after treatment (↓8.2%; 95% CI: 7.7-8.7; p < 0.001; Figure 2).

  PMID:25410844 · one of two readings recorded this

• sputum eosinophil count, percentage, pooled pre- vs post-treatment

  decreases, six-fold mean reduction (↓8.2%; 95% CI: 7.7-8.7; p < 0.001), n = 198

  The pooled analysis (n = 198) showed a six-fold mean reduction in the number of sputum eosinophils after treatment (↓8.2%; 95% CI: 7.7-8.7; p < 0.001; Figure 2).

  PMID:25410844 · one of two readings recorded this

• sputum eosinophil percentage, sputum IL-5, sputum eosinophil cationic protein, and post-bronchodilator FEV1, pooled pre- versus post-treatment with oral prednisone or prednisolone in asthma patients

  decreases, six-fold mean reduction in sputum eosinophils (down 8.2%; 95% CI 7.7-8.7), n = 198

  Not recorded as a finding: the result compares a group with itself, not with a control

  The pooled analysis (n = 198) showed a six-fold mean reduction in the number of sputum eosinophils after treatment (↓8.2%; 95% CI: 7.7-8.7; p < 0.001; Figure 2).

  PMID:25410844 · one of two readings recorded this

• sputum eosinophils

  decreases, six-fold mean reduction (down 8.2%; 95% CI 7.7-8.7), n = 198

  The pooled analysis (n = 198) showed a six-fold mean reduction in the number of sputum eosinophils after treatment (↓8.2%; 95% CI: 7.7-8.7; p < 0.001; Figure 2).

  PMID:25410844 · one of two readings recorded this

• sputum IL-5, pg/mL, pooled pre- vs post-treatment

  decreases, approximately four-fold mean decrease (↓83.6; 95% CI: 52.5-83.6; p < 0.001), n = 114

  Among studies evaluating IL-5 (in pg/mL) before and after treatment with prednisone or prednisolone (n = 114), there was an approximately four-fold mean decrease in IL-5 levels (↓83.6; 95% CI: 52.5-83.6; p < 0.001; Figure 3).

  PMID:25410844 · one of two readings recorded this

• sputum IL-5

  decreases, approximately four-fold mean decrease (down 83.6 pg/mL; 95% CI 52.5-83.6), n = 114

  Among studies evaluating IL-5 (in pg/mL) before and after treatment with prednisone or prednisolone (n = 114), there was an approximately four-fold mean decrease in IL-5 levels (↓83.6; 95% CI: 52.5-83.6; p < 0.001; Figure 3).

  PMID:25410844 · one of two readings recorded this

• North Star Ambulatory Assessment linearized score, 48-week change

  decreases

  Deflazacort-treated patients experienced significantly lower functional decline over 48 weeks.

  PMID:31599456 · one of two readings recorded this

• overall survival (OS)

  increases, pooled HR CD38 0.56 (95%CI 0.41-0.70); SLAMF7 0.69 (95%CI 0.56-0.82)

  Two RCTs about the MAbs targeting CD38 and three RCTs about the MAbs targeting SLAMF7 provided OS and HR with the pooled HRs being 0.56 (95%CI 0.41–0.70) and 0.69 (95%CI 0.56–0.82), respectively.

  PMID:34488679 · one of two readings recorded this

• progression-free survival (PFS)

  increases, pooled HR CD38 vs control 0.45 (95%CI 0.40-0.50)

  The pooled HRs for the PFS of the MAbs targeting CD38, SLAMF7, and PD-1/PD-L1 groups vs their corresponding control groups were 0.45 (95%CI 0.40–0.50), 0.68 (95%CI 0.57–0.79), and 1.42 (95%CI 0.95–1.88), respectively.

  PMID:34488679 · one of two readings recorded this

• progression-free survival

  pooled HRs for CD38 0.45 (95% CI 0.40-0.50), SLAMF7 0.68 (95% CI 0.57-0.79), PD-1/PD-L1 1.42 (95% CI 0.95-1.88) vs corresponding control groups, n = 5367

  The pooled HRs for the PFS of the MAbs targeting CD38, SLAMF7, and PD-1/PD-L1 groups vs their corresponding control groups were 0.45 (95%CI 0.40–0.50), 0.68 (95%CI 0.57–0.79), and 1.42 (95%CI 0.95–1.88), respectively.

  PMID:34488679 · one of two readings recorded this

• change in facial swelling from T1 to T2

  no effect, p = 0.7

  no statistically significant differences have been found between the groups (PG: 2.1 ± 1.5; CG: 2.0 ± 1.3; p = 0.7)

  PMID:37653378 · one of two readings recorded this

• correlation of facial swelling with surgery time

  increases, p = 0.001

  longer surgical time was related to higher facial swelling at both T1 and T2 (p < 0.001)

  PMID:37653378 · one of two readings recorded this

• facial swelling (3D scan)

  decreases, p = 0.02

  at T1, PG showed a significantly lower facial swelling compared to CG (PG: 3.3 ± 2.1 mm; CG: 4.2 ± 1.7 mm; p = 0.02)

  PMID:37653378 · one of two readings recorded this

• facial swelling (3D scan)

  decreases, p = 0.0005

  Similar results were recorded comparing the groups one week after surgery (PG: 1.2 ± 1.2; CG: 2.1 ± 1.3; p = 0.0005)

  PMID:37653378 · one of two readings recorded this

• facial swelling by three-dimensional face scan, Bellus3D app with 3D Slicer model-to-model distance, in millimetres at 2 and 7 days

  decreases, PG 3.3 versus CG 4.2 mm at T1, p = 0.02

  Not recorded as a finding: no_outcome_node: no outcome for 3D-scan facial swelling

  According to the primary predictor variable, at T1, PG showed a significantly lower facial swelling compared to CG (PG: 3.3 ± 2.1 mm; CG: 4.2 ± 1.7 mm; p = 0.02).

  PMID:37653378 · one of two readings recorded this

• facial swelling by three-dimensional face scan, Bellus3D camera with 3D Slicer model-to-model distance, in millimetres

  decreases, p = 0.02

  Not recorded as a finding: no outcome node for 3D facial swelling

  According to the primary predictor variable, at T1, PG showed a significantly lower facial swelling compared to CG (PG: 3.3 ± 2.1 mm; CG: 4.2 ± 1.7 mm; p = 0.02).

  PMID:37653378 · one of two readings recorded this

• facial swelling vs baseline, all patients

  increases

  All patients showed an increase in facial swelling after surgery compared to T0 (T0-T1: 3.8 ± 2 mm; T0-T2: 1.7 ± 1.3 mm)

  PMID:37653378 · one of two readings recorded this

• facial swelling vs baseline, all patients

  increases

  All patients showed an increase in facial swelling after surgery compared to T0 (T0-T1: 3.8 ± 2 mm; T0-T2: 1.7 ± 1.3 mm)

  PMID:37653378 · one of two readings recorded this

• maximum mouth opening (trismus), maximum inter-incisal distance with a calibrated rule, in millimetres

  no effect, PG 35.6 mm versus CG 33.7 mm at T1, no difference

  Not recorded as a finding: no outcome node for maximum mouth opening

  At T1, the maximum buccal opening was significantly reduced with no difference between PG (35.6 ± 8.2 mm) and CG (33.7 ± 7.3 mm) (p > 0.05).

  PMID:37653378 · one of two readings recorded this

• maximum mouth opening (trismus), maximum inter-incisal distance with a calibrated rule

  no effect, PG 35.6 versus CG 33.7 mm at T1, p > 0.05

  Not recorded as a finding: no_outcome_node: no outcome for maximum mouth opening or trismus

  At T1, the maximum buccal opening was significantly reduced with no difference between PG (35.6 ± 8.2 mm) and CG (33.7 ± 7.3 mm) (p > 0.05).

  PMID:37653378 · one of two readings recorded this

• maximum mouth opening

  Before surgery, all patients showed good values of buccal opening (44.9 ± 4.6 mm; PG: 44.9 ± 4.5 mm; CG: 44.8 ± 4.8 mm)

  PMID:37653378 · one of two readings recorded this

• maximum mouth opening

  no effect, p = 0.05

  At T1, the maximum buccal opening was significantly reduced with no difference between PG (35.6 ± 8.2 mm) and CG (33.7 ± 7.3 mm) (p > 0.05)

  PMID:37653378 · one of two readings recorded this

• maximum mouth opening

  no effect, p = 0.05

  The inflammatory effect persisted one week after surgery in both groups (PG: 33.2 ± 14.4 mm; CG: 33.7 ± 13.1 mm; p > 0.05)

  PMID:37653378 · one of two readings recorded this

• pain (VAS), all patients

  increases

  After surgery, the pain trend increased at T1 (3.9 ± 1.8) and then reduced at T2 (1.4 ± 1.2)

  PMID:37653378 · one of two readings recorded this

• pain (VAS), all patients

  decreases

  After surgery, the pain trend increased at T1 (3.9 ± 1.8) and then reduced at T2 (1.4 ± 1.2)

  PMID:37653378 · one of two readings recorded this

• pain (VAS)

  All patients showed low values of local pain at T0 (0.83 ± 1.2; PG: 0.75 ± 1.2; CG: 0.9 ± 1.1)

  PMID:37653378 · one of two readings recorded this

• pain (VAS)

  decreases, p = 0.0006

  PG showed significantly lower pain values compared to CG, both at T1 (PG: 3.1 ± 1.5; CG: 4.6 ± 1.8; p = 0.0006) and T2 (PG: 1.0 ± 0.8; CG: 1.9 ± 1.4; p = 0.0063)

  PMID:37653378 · one of two readings recorded this

• pain (VAS)

  decreases, p = 0.0063

  PG showed significantly lower pain values compared to CG, both at T1 (PG: 3.1 ± 1.5; CG: 4.6 ± 1.8; p = 0.0006) and T2 (PG: 1.0 ± 0.8; CG: 1.9 ± 1.4; p = 0.0063)

  PMID:37653378 · one of two readings recorded this

• surgery time

  no effect, p = 0.05

  Surgery time recorded a mean value of 15.6 ± 3.7 min, without statistically significant difference between the groups (PG: 15.7 ± 3.9 min; CG: 15.6 ± 3.5 min; p > 0.05)

  PMID:37653378 · one of two readings recorded this

• complete response at initial assessment

  n = 56

  In Arm A, CRs were 35 (62.50%); PRs, 7 (12.50%); MRs, 2 (3.57%); and NRs, 12 (21.43%)

  PMID:38231017 · one of two readings recorded this

• complete response at initial assessment

  n = 49

  In Arm B, CRs were 31 (63.27%); PRs, 11 (22.45%); MRs, 4 (8.16%); and NRs, 3 (6.12%)

  PMID:38231017 · one of two readings recorded this

• disease-free survival of responders

  with 89.84% (95% CI, 77.34-100.00) in Arm A and 70.88% (95% CI, 51. 80-96.79) in Arm B

  PMID:38231017 · one of two readings recorded this

• disease-free survival of responders

  overall DFS was estimated to be 81.11% (95% CI, 69.20-95.06) at 48 months from day 180

  PMID:38231017 · one of two readings recorded this

• final response (CR + R), IWG criteria post hoc

  no effect, p = 0.8907, n = 82

  Final response | CR + R | 26 (60.47%) | 23 (58.97%) |.8907

  PMID:38231017 · one of two readings recorded this

• initial, final and persistent platelet response rate (complete, partial or minimal response by platelet count and bleeding score) in newly diagnosed primary immune thrombocytopenia, prednisone 1 mg/kg/day versus high-dose dexamethasone 40 mg/day

  p = 0.0284, n = 105

  Not recorded as a finding: the comparison was against another active treatment

  The difference in initial response rate between the 2 arms was statistically significant (P =.0284), in favor of Arm B (Table 7).

  PMID:38231017 · one of two readings recorded this

• initial no response (NR)

  n = 105

  NR | 12 (21.43%) | 3 (6.12%)

  PMID:38231017 · one of two readings recorded this

• initial response (CR + R), IWG criteria post hoc

  no effect, p = 0.0592, n = 105

  Initial response | CR + R | 44 (78.57%) | 45 (91.84%) |.0592

  PMID:38231017 · one of two readings recorded this

• loss of response + NR at final assessment

  n = 82

  Loss of response + NR | 17 (39.53%) | 16 (41.03%)

  PMID:38231017 · one of two readings recorded this

• overall survival

  overall survival was estimated to be 100% (95% confidence interval [CI], 100-100) at 48 months

  PMID:38231017 · one of two readings recorded this

• persistent no response (NR)

  n = 67

  NR | 6 (19.35%) | 16 (44.40%)

  PMID:38231017 · one of two readings recorded this

• persistent response (CR + R), IWG criteria post hoc

  increases, p = 0.0292, n = 67

  Persistent response | CR + R | 25 (80.65%) | 20 (55.56%) |.0292

  PMID:38231017 · one of two readings recorded this

• relapses

  In total, 7 relapses occurred: 2 in Arm A and 5 in Arm B

  PMID:38231017 · one of two readings recorded this

• total final response (CR + PR + MR)

  no effect, p = 0.8907, n = 82

  Final response | CR + PR + MR | 26 (60.47%) | 23 (58.97%) |.8907

  PMID:38231017 · one of two readings recorded this

• total initial response (CR + PR + MR)

  decreases, p = 0.0284, n = 105

  Initial response | CR + PR + MR | 44 (78.57%) | 46 (93.88%) |.0284

  PMID:38231017 · one of two readings recorded this

• total persistent response (CR + PR + MR)

  increases, p = 0.0292, n = 67

  Persistent response | CR + PR + MR | 25 (80.65%) | 20 (55.56%) |.0292

  PMID:38231017 · one of two readings recorded this

• 180-day survival among Day-7 Lille non-responders (landmark)

  no effect, p = 0.139, n = 27

  12 of 13 (92.3%) participants classified as non-responders per Day-7 Lille score survived 180 days, in comparison to 10 of 14 (71.4%) in the A+Z group (P = 0.139)

  PMID:38342441 · one of two readings recorded this

• 90-day survival, participants older than 44 years

  increases, p = 0.013

  but the difference reached statistical significance in participants older than 44 years old [93.5% vs 61.1%, respectively, P=0.013]

  PMID:38342441 · one of two readings recorded this

• 90-day survival, participants younger than 44 years

  no effect, p = 0.73

  There was no significant difference in survival between the two groups in participants younger than 44 years old [85.3% in PRED vs 78.4% in A+Z, P =0.73)

  PMID:38342441 · one of two readings recorded this

• acute kidney injury incidence (Fine-Gray)

  increases, p = 0.001, n = 147

  AKI occurred in 44.6% (33/74) participants in the A+Z group during the study period, more than doubled that in the PRED group 21.9% (16/73) (p=0.001 per Fine-Gray test)

  PMID:38342441 · one of two readings recorded this

• acute kidney injury (secondary endpoint)

  increases, p = 0.0008, n = 147

  AKI (44.6% (33/74) versus 21.9% (16/73), HR = 2.67, 95% CI: [1.49, 4.80], P=0.0008)

  PMID:38342441 · one of two readings recorded this

• acute kidney injury serious adverse events

  increases, p = 0.005

  The most common SAE was AKI (15 events in the PRED group versus 36 events in the A+Z group, P = 0.005)

  PMID:38342441 · one of two readings recorded this

• death contributed to by severe infection

  no effect, p = 0.097, n = 147

  [2/73 (3%) in the PRED group versus 8/74 (11%) in the A+Z group, P = 0.097]

  PMID:38342441 · one of two readings recorded this

• death while experiencing AKI

  increases, p = 0.022, n = 147

  The proportion of participants that died while experiencing AKI was also greater in the A+Z [14/74 (18.9%)] than that in the PRED group [4/73 (5.5%), P = 0.022]

  PMID:38342441 · one of two readings recorded this

• deaths, per-protocol analysis

  decreases, p = 0.0282

  Seven deaths were observed in the PRED group compared to 18 in the A+Z group (p=0.0282)

  PMID:38342441 · one of two readings recorded this

• infection incidence (Fine-Gray)

  no effect, p = 0.3887, n = 147

  In the PRED group, 27.4% (20/73) participants experienced infections versus 31.1% (23/74) in the A+Z group (P=0.3887 per Fine-Gray test)

  PMID:38342441 · one of two readings recorded this

• infections after stopping prednisone/prednisone placebo

  no effect, p = 0.999, n = 27

  The rates of infections after stopping prednisone/prednisone placebo were 23.1% (3/13) in the PRED group vs 28.6% (4/14) in the A+Z group (p>0.999)

  PMID:38342441 · one of two readings recorded this

• liver transplant

  n = 147

  One of 73 (1.4%) participants in the PRED group and 4 of 74 (5.4%) in the A+Z group received a liver transplant

  PMID:38342441 · one of two readings recorded this

• MELD increase by more than 5 points

  increases, p = 0.0002, n = 147

  The A+Z arm had a higher frequency of MELD increase by >5 points [28.4% (21/74) versus 4.1% (3/73), HR = 7.56, 95% CI: (2.26, 25.30), P =0.0002)

  PMID:38342441 · one of two readings recorded this

• overall 90-day mortality, adjusted Cox regression

  decreases, p = 0.018, n = 147

  adjusted HR = 0.34, 95% CI [0.14, 0.83], P=0.018

  PMID:38342441 · one of two readings recorded this

• overall mortality at 90 days (primary), transplant-free survival, acute kidney injury, infection; prednisone 40 mg daily for 30 days versus anakinra plus zinc in severe alcohol-associated hepatitis

  decreases, p = 0.018, n = 147

  Not recorded as a finding: the comparison was against another active treatment

  A Cox regression analysis with baseline MELD score and clinical site as stratification factor further confirmed that PRED was associated with lower overall 90-day mortality (adjusted HR = 0.34, 95% CI [0.14, 0.83], P=0.018).

  PMID:38342441 · one of two readings recorded this

• overall survival at 180 days

  no effect, p = 0.205, n = 147

  survival at 30 and 180 days, were 97% and 81% in the PRED versus 85% and 68% in the A+Z group (respective HR and 95%CI were 0.23 [0.05, 1.06] and 0.62 [0.30, 1.30], P=0.059 and P=0.205)

  PMID:38342441 · one of two readings recorded this

• overall survival at 30 days

  no effect, p = 0.059, n = 147

  survival at 30 and 180 days, were 97% and 81% in the PRED versus 85% and 68% in the A+Z group (respective HR and 95%CI were 0.23 [0.05, 1.06] and 0.62 [0.30, 1.30], P=0.059 and P=0.205)

  PMID:38342441 · one of two readings recorded this

• overall survival at 90 days

  increases, n = 147

  At 90 days, 66 of 73 participants in the PRED group survived, as compared to 55 out of 74 in the A+Z group, with an estimated overall 90-day survival of 90% and 70%, respectively

  PMID:38342441 · one of two readings recorded this

• overall survival (mortality) at 90 days, severe alcohol-associated hepatitis, prednisone 40 mg orally once daily for 30 days versus anakinra plus zinc sulfate, Cox regression stratified by MELD and site; also transplant-free survival and acute kidney injury incidence

  decreases, adjusted HR 0.34 (95% CI 0.14 to 0.83) for 90-day mortality, prednisone versus anakinra plus zinc (active comparator, not placebo), p = 0.018

  Not recorded as a finding: the comparison was against another active treatment

  A Cox regression analysis with baseline MELD score and clinical site as stratification factor further confirmed that PRED was associated with lower overall 90-day mortality (adjusted HR = 0.34, 95% CI [0.14, 0.83], P=0.018).

  PMID:38342441 · one of two readings recorded this

• participants completing all study visits

  n = 147

  In the PRED group 50.7% (37/73) participants completed all study visits versus 40.5% (30/74) in the A+Z group

  PMID:38342441 · one of two readings recorded this

• protocol-mandated discontinuation for Lille score above 0.45

  Lille score >0.45 (13 versus 14)

  PMID:38342441 · one of two readings recorded this

• protocol-mandated discontinuation for MELD score increase

  MELD score increase by > 5 points (3 versus 21)

  PMID:38342441 · one of two readings recorded this

• protocol-mandated discontinuation for serious adverse events

  SAEs (13 versus 14)

  PMID:38342441 · one of two readings recorded this

• serious adverse events, participants affected

  no effect, p = 0.109, n = 147

  111 SAEs occurred in 56.2% (41/73) participants in the PRED group versus 138 SAEs in 66.2% (49/74) (participants in the A+Z group (P = 0.109)

  PMID:38342441 · one of two readings recorded this

• severe infections as share of infections

  no effect, p = 0.45, n = 56

  In the PRED group 40% (10/25) of infections were severe vs 58.1% (18/31) in the A+Z group (P = 0.45)

  PMID:38342441 · one of two readings recorded this

• transplant-free survival at 90 days, per-protocol analysis

  increases, p = 0.0069

  The 90-day transplant-free survival similarly favored PRED (p= 0.0069)

  PMID:38342441 · one of two readings recorded this

• transplant-free survival at 90 days

  increases, p = 0.004, n = 147

  The 90-day transplant-free survival rates for the PRED and A+Z groups were 88% and 64%, respectively (HR = 0.30, 95% CI: [0.13, 0.69], P=0.004)

  PMID:38342441 · one of two readings recorded this

• correlation of Ang-2 with clinical risk score

  increases

  while Ang-2 (0.37), IL-6 (0.34) and chromogranin A (0.33) were also found to correlate with increasing risk

  PMID:38347114 · one of two readings recorded this

• correlation of chromogranin A with clinical risk score

  increases

  while Ang-2 (0.37), IL-6 (0.34) and chromogranin A (0.33) were also found to correlate with increasing risk

  PMID:38347114 · one of two readings recorded this

• correlation of IL-6 with clinical risk score

  increases

  while Ang-2 (0.37), IL-6 (0.34) and chromogranin A (0.33) were also found to correlate with increasing risk

  PMID:38347114 · one of two readings recorded this

• correlation of osteopontin with clinical risk score

  increases

  OPN was found to have the strongest correlation with increasing clinical risk score (Spearman correlation coefficient=0.61)

  PMID:38347114 · one of two readings recorded this

• median overall survival

  increases

  median OS improved from 17.4 (95% CI: 14.1-20.3) to 19.7 months (95% CI: 16.3-21.8) in men with high OPN levels upon addition of B to DP

  PMID:38347114 · one of two readings recorded this

• median overall survival

  no effect

  The median OS for low OPN patients was 28.5 (95% CI: 25.2-31.9) months in the DP arm and 28.5 (95% CI: 25.1-33.0) months in the DP+B arm

  PMID:38347114 · one of two readings recorded this

• median progression-free survival

  increases

  in high OPN patients, the median PFS improved from 5.9 (95% CI: 5.1-7.2) to 8.3 (95% CI: 7.3-10.2) with the addition of B to DP

  PMID:38347114 · one of two readings recorded this

• median progression-free survival

  increases

  The median PFS in low OPN patients improved from 9.4 months (95% CI: 8.2-10.5) to 11.2 months (95% CI: 10.1-12.6) with the addition of B to DP

  PMID:38347114 · one of two readings recorded this

• median progression-free survival

  no effect

  Median PFS time was 8.8 months for the biomarker selected population and 8.5 months for the overall population

  PMID:38347114 · one of two readings recorded this

• overall survival by BMP-9 level

  decreases

  BMP-9 (OS of 21.3 vs. 25.1 months in marker low vs. high groups, HR 0.9; 95% CI= 0.8-1.0)

  PMID:38347114 · one of two readings recorded this

• overall survival, multivariable adjusted for risk score

  increases

  Ang-2 (HR=1.2, 95% CI=1.1-1.3)

  PMID:38347114 · one of two readings recorded this

• overall survival, multivariable adjusted for risk score

  increases

  HGF (HR=1.1, 95% CI=1.0-1.2

  PMID:38347114 · one of two readings recorded this

• overall survival, multivariable adjusted for risk score

  increases

  ICAM-1 (HR=1.5, 95% CI=1.2-1.9)

  PMID:38347114 · one of two readings recorded this

• overall survival, multivariable adjusted for risk score

  increases

  TIMP-1 (HR=1.3, 95% CI=1.1-1.5)

  PMID:38347114 · one of two readings recorded this

• overall survival, multivariable adjusted for risk score

  increases

  TSP-2 (HR=1.2, 95% CI=1.0-1.3)

  PMID:38347114 · one of two readings recorded this

• overall survival, multivariable adjusted for risk score

  increases

  VEGF-R3 (HR=1.4, 95% CI=1.2-1.7)

  PMID:38347114 · one of two readings recorded this

• overall survival, multivariable adjusted for risk score

  increases

  VEGF (HR=1.1, 95% CI=1.0-1.2)

  PMID:38347114 · one of two readings recorded this

• overall survival, treatment-by-biomarker interaction

  unclear, p = 0.063

  consisting of OPN (Pintx=0.063), PDGF-BB (Pintx=0.064), and PDGF-AA (Pintx=0.094)

  PMID:38347114 · one of two readings recorded this

• overall survival, treatment-by-biomarker interaction

  unclear, p = 0.094

  consisting of OPN (Pintx=0.063), PDGF-BB (Pintx=0.064), and PDGF-AA (Pintx=0.094)

  PMID:38347114 · one of two readings recorded this

• overall survival, treatment-by-biomarker interaction

  unclear, p = 0.064

  consisting of OPN (Pintx=0.063), PDGF-BB (Pintx=0.064), and PDGF-AA (Pintx=0.094)

  PMID:38347114 · one of two readings recorded this

• progression-free survival difference, low vs high biomarker level

  decreases

  Patients with low levels of the biomarkers (less than the observed median levels) had an average of 1.7 month longer median PFS than patients will high levels of the biomarkers

  PMID:38347114 · one of two readings recorded this

• progression-free survival, treatment-by-OPN interaction (multivariable)

  increases, p = 0.027

  in both univariate (Pintx=0.016), and multivariable analysis (Pintx=0.027)

  PMID:38347114 · one of two readings recorded this

• progression-free survival, treatment-by-OPN interaction (univariate)

  increases, p = 0.016

  in both univariate (Pintx=0.016), and multivariable analysis (Pintx=0.027)

  PMID:38347114 · one of two readings recorded this

• DAS at visits after vs before/without diabetes

  increases, p = 0.03

  in visits of DM patients before diagnosis and in patients without diabetes, mean (SD) DAS 2.07 (1.06) vs 1.94 (1.06), p=0.03

  PMID:38688692 · one of two readings recorded this

• development of diabetes by any definition (random plasma glucose of 11.1 mmol/L or more on two occasions, or hypoglycaemic medication), Cox regression with time-varying prednisone variables; random glucose level; hyperglycaemia at 7.8 mmol/L or more

  no effect, n = 504

  Not recorded as a finding: a node exists but the paper states a different instrument or population

  Likewise, none of the prednisone variables were significantly associated with an increased risk of developing hyperglycaemia in the main analyses (table 4), nor with the development of diabetes.

  PMID:38688692 · one of two readings recorded this

• development of diabetes mellitus (random plasma glucose of 11.1 mmol/L or more on at least two occasions, or use of hypoglycaemic agents), hyperglycaemia (random glucose 7.8 mmol/L or more) and random plasma glucose over time, in association with time-varying prednisone dose and exposure in early rheumatoid arthritis, mixed-effects and Cox models

  no effect, no significant association between prednisone use and diabetes in sensitivity analyses

  Not recorded as a finding: a node exists but the paper states a different instrument or population

  There was no significant association between prednisone use and diabetes in sensitivity analyses.

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect, n = 504

  Any previous prednisone use* | 0.72 | 0.28 to 1.84 | 0.72 | 0.33 to 1.51

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect

  Any previous prednisone use* | 0.72 | 0.28 to 1.84 | 0.72 | 0.33 to 1.51

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect, n = 504

  Cumulative prednisone dose* | 0.96 | 0.89 to 1.05 | 0.97 | 0.90 to 1.03

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect

  Cumulative prednisone dose* | 0.96 | 0.89 to 1.05 | 0.97 | 0.90 to 1.03

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  increases, n = 504

  Current DAS† | 1.80 | 1.19 to 2.72 | 1.80 | 1.28 to 2.53

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  increases

  Current DAS† | 1.80 | 1.19 to 2.72 | 1.80 | 1.28 to 2.53

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect, n = 504

  Current prednisone dose* | 1.07 | 0.98 to 1.16 | 1.07 | 1.00 to 1.15

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect

  Current prednisone dose* | 1.07 | 0.98 to 1.16 | 1.07 | 1.00 to 1.15

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect, n = 504

  Maximum previous prednisone dose* | 0.97 | 0.95 to 1.04 | 1.00 | 0.96 to 1.03

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect

  Maximum previous prednisone dose* | 0.97 | 0.95 to 1.04 | 1.00 | 0.96 to 1.03

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect, n = 504

  Previous time on prednisone* | 0.97 | 0.91 to 1.02 | 0.97 | 0.93 to 1.01

  PMID:38688692 · one of two readings recorded this

• diabetes by any definition (hazard ratio)

  no effect

  Previous time on prednisone* | 0.97 | 0.91 to 1.02 | 0.97 | 0.93 to 1.01

  PMID:38688692 · one of two readings recorded this

• diabetes development

  no effect, p = 1, n = 504

  Diabetes development, % | 6.1 | 6.3 | 1.00

  PMID:38688692 · one of two readings recorded this

• diabetes per 0.2 point DAS increase (text)

  increases, n = 504

  (or an HR of 1.12 (95% CI 1.05 to 1.21) per 0.2 point DAS increase)

  PMID:38688692 · one of two readings recorded this

• diabetes per one-point higher DAS (text)

  increases, p = 0.001, n = 504

  a one-point higher DAS over time was associated with an HR of 1.80 (95% CI 1.28 to 2.53, p=0.001) for developing diabetes in the main analyses

  PMID:38688692 · one of two readings recorded this

• diabetes prevalence by treatment arm

  no effect, p = 0.83

  Patients with diabetes were equally distributed among the treatment arms, ranging from 5.5% in arm 4 to 8.3% in arm 2 (p=0.83)

  PMID:38688692 · one of two readings recorded this

• duration of a prednisone course (median)

  n = 240

  The median (IQR) duration of a prednisone course was 9 (6–12) months

  PMID:38688692 · one of two readings recorded this

• glucose increase per point DAS after first hyperglycaemia (text)

  increases

  increase in glucose of 0.08 mmol/L (95% CI 0.04 to 0.12) per point increase in DAS in visits after the first hyperglycaemia

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect, n = 504

  Any previous prednisone use* | 0.03 | −0.09 to 0.14 | −0.02 | −0.13 to 0.08

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect

  Any previous prednisone use* | 0.03 | −0.09 to 0.14 | −0.02 | −0.13 to 0.08

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect, n = 504

  Cumulative prednisone dose* | −0.00 | −0.00 to 0.00 | −0.00 | −0.01 to 0.01

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect

  Cumulative prednisone dose* | −0.00 | −0.00 to 0.00 | −0.00 | −0.01 to 0.01

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect, n = 504

  Current DAS† | 0.03 | −0.01 to 0.06 | 0.08 | 0.04 to 0.12

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  increases

  Current DAS† | 0.03 | −0.01 to 0.06 | 0.08 | 0.04 to 0.12

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect, n = 504

  Current prednisone dose* | 0.00 | −0.01 to 0.01 | 0.01 | −0.01 to 0.02

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect

  Current prednisone dose* | 0.00 | −0.01 to 0.01 | 0.01 | −0.01 to 0.02

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect, n = 504

  Maximum previous prednisone dose* | 0.00 | −0.00 to 0.01 | −0.00 | −0.01 to 0.01

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect

  Maximum previous prednisone dose* | 0.00 | −0.00 to 0.01 | −0.00 | −0.01 to 0.01

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect, n = 504

  Previous time on prednisone* | −0.00 | −0.01 to 0.00 | −0.00 | −0.01 to 0.00

  PMID:38688692 · one of two readings recorded this

• glucose over time (beta)

  no effect

  Previous time on prednisone* | −0.00 | −0.01 to 0.00 | −0.00 | −0.01 to 0.00

  PMID:38688692 · one of two readings recorded this

• glucose over time, mean (SD)

  no effect, p = 0.05, n = 504

  Glucose over time, mean (SD) | 5.7 | (1.8) | 5.7 | (1.4) | 0.05

  PMID:38688692 · one of two readings recorded this

• glucose over time, mean (SD)

  increases, p = 0.001, n = 504

  Glucose over time, mean (SD) | 5.5 | (1.4) | 8.1 | (3.3) | <0.001

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect, n = 504

  Any previous prednisone use* | 1.22 | 0.90 to 1.65 | 0.89 | 0.69 to 1.14

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect

  Any previous prednisone use* | 1.22 | 0.90 to 1.65 | 0.89 | 0.69 to 1.14

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect, n = 504

  Cumulative prednisone dose* | 1.01 | 0.99 to 1.04 | 0.99 | 0.97 to 1.00

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect

  Cumulative prednisone dose* | 1.01 | 0.99 to 1.04 | 0.99 | 0.97 to 1.00

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect, n = 504

  Current DAS† | 1.04 | 0.94 to 1.16 | 1.29 | 1.17 to 1.42

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  increases

  Current DAS† | 1.04 | 0.94 to 1.16 | 1.29 | 1.17 to 1.42

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect, n = 504

  Current prednisone dose* | 1.01 | 0.98 to 1.04 | 1.03 | 1.00 to 1.06

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect

  Current prednisone dose* | 1.01 | 0.98 to 1.04 | 1.03 | 1.00 to 1.06

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect, n = 504

  Maximum previous prednisone dose* | 1.00 | 0.99 to 1.02 | 1.00 | 0.99 to 1.01

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect

  Maximum previous prednisone dose* | 1.00 | 0.99 to 1.02 | 1.00 | 0.99 to 1.01

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect, n = 504

  Previous time on prednisone* | 1.00 | 0.99 to 1.02 | 0.99 | 0.98 to 1.00

  PMID:38688692 · one of two readings recorded this

• hyperglycaemia ≥7.8 (odds ratio)

  no effect

  Previous time on prednisone* | 1.00 | 0.99 to 1.02 | 0.99 | 0.98 to 1.00

  PMID:38688692 · one of two readings recorded this

• mean DAS over time

  increases, p = 0.03, n = 504

  Mean DAS (SD) over time | 1.9 | (1.1) | 2.1 | (1.1) | 0.03

  PMID:38688692 · one of two readings recorded this

• mean glucose at visits with vs without prednisone

  no effect, p = 0.94

  The mean (SD) glucose level at visits with prednisone (1220/12 184 visits) was 5.7 (1.7) mmol/L, which was similar to mean (SD) glucose levels at visits without prednisone (10 964/12 184 visits, 5.7 (1.3) mmol/L), p=0.94)

  PMID:38688692 · one of two readings recorded this

• mean glucose before vs after intramuscular glucocorticoids

  no effect, p = 0.21

  The mean (SD) glucose on visits before imGCs was 5.2 (1.1) compared with 5.5 (1.4) on visits after imGCs (p=0.21, paired t-test)

  PMID:38688692 · one of two readings recorded this

• mean glucose by disease activity category (crude)

  no effect

  In visits where patients were in remission, low, moderate and high disease activity, mean (SD) glucose was 5.7 (1.7), 5.7 (1.6), 5.8 (1.8) and 5.8 (2.0), respectively

  PMID:38688692 · one of two readings recorded this

• mean glucose by disease activity category (crude)

  no effect

  In visits where patients were in remission, low, moderate and high disease activity, mean (SD) glucose was 5.7 (1.7), 5.7 (1.6), 5.8 (1.8) and 5.8 (2.0), respectively

  PMID:38688692 · one of two readings recorded this

• mean glucose by disease activity category (crude)

  no effect

  In visits where patients were in remission, low, moderate and high disease activity, mean (SD) glucose was 5.7 (1.7), 5.7 (1.6), 5.8 (1.8) and 5.8 (2.0), respectively

  PMID:38688692 · one of two readings recorded this

• mean glucose by disease activity category (crude)

  no effect

  In visits where patients were in remission, low, moderate and high disease activity, mean (SD) glucose was 5.7 (1.7), 5.7 (1.6), 5.8 (1.8) and 5.8 (2.0), respectively

  PMID:38688692 · one of two readings recorded this

• patients who developed diabetes

  n = 504

  During the study, 31 (6.2%) patients developed DM based on our definitions

  PMID:38688692 · one of two readings recorded this

• patients with hyperglycaemia

  no effect, p = 0.72, n = 504

  Patients with hyperglycaemia, % | 45 | 47 | 0.72

  PMID:38688692 · one of two readings recorded this

• patients with hyperglycaemia

  increases, p = 0.001, n = 504

  Patients with hyperglycaemia, % | 43 | 94 | <0.001

  PMID:38688692 · one of two readings recorded this

• recurrence of hyperglycaemia per mg current prednisone dose (text)

  no effect, p = 0.026

  OR 1.03, 95% CI 1.00 to 1.06 for each mg increase in the current prednisone dose used, p=0.026

  PMID:38688692 · one of two readings recorded this

• recurrence of hyperglycaemia per point DAS (text)

  increases

  OR 1.29 for each point higher DAS, 95% CI 1.17 to 1.42

  PMID:38688692 · one of two readings recorded this

• time from baseline to development of diabetes (median)

  n = 31

  The median (IQR) time from baseline to development of DM was 6.3 (3.3–7.5) years

  PMID:38688692 · one of two readings recorded this

• AKI phenotype: acute tubular necrosis (ATN)

  no effect

  ATN (24% A+Z vs. 25% PRED) as the most common cause, followed by prerenal (12% A + Z vs. 31% PRED)

  PMID:39028887 · one of two readings recorded this

• AKI phenotype: prerenal

  ATN (24% A+Z vs. 25% PRED) as the most common cause, followed by prerenal (12% A + Z vs. 31% PRED)

  PMID:39028887 · one of two readings recorded this

• Complete recovery from AKI

  no effect

  Complete recovery from AKI was noted in 9/33 (27.3%) versus 6/16 (37.5%) participants

  PMID:39028887 · one of two readings recorded this

• Correlation between MAP and serum creatinine, A+Z, day 14

  decreases, p = 0.001

  This negative correlation between MAP and sCr became significant on day 7 (R = −0.30, p =0.017) and peaked on days 14 (R = −0.53, p< 0.001) and 28 (R =−0.37, p =0.017)

  PMID:39028887 · one of two readings recorded this

• Correlation between MAP and serum creatinine, A+Z, day 28

  decreases, p = 0.017

  This negative correlation between MAP and sCr became significant on day 7 (R = −0.30, p =0.017) and peaked on days 14 (R = −0.53, p< 0.001) and 28 (R =−0.37, p =0.017)

  PMID:39028887 · one of two readings recorded this

• Correlation between MAP and serum creatinine, A+Z, day 7

  decreases, p = 0.017

  This negative correlation between MAP and sCr became significant on day 7 (R = −0.30, p =0.017) and peaked on days 14 (R = −0.53, p< 0.001) and 28 (R =−0.37, p =0.017)

  PMID:39028887 · one of two readings recorded this

• Correlation between MAP and serum creatinine, PRED, day 28

  decreases, p = 0.014

  a negative correlation was found between MAP and sCr in PRED-treated participants on day 28 (R =−0.34, p =0.014)

  PMID:39028887 · one of two readings recorded this

• Diuretic use before AKI onset

  no effect, p = 0.272

  diuretic use was similar in both treatment arms (n= 10/33 [30.3%] A+Z vs. n= 7/15 [46.7%] PRED, p= 0.272)

  PMID:39028887 · one of two readings recorded this

• Gastrointestinal bleed before AKI onset

  no effect, p = 1

  a gastrointestinal bleed (n =4/33 [12.1%] A+Z vs. n= 2/16 [13.3%] PRED, p= 1.000)

  PMID:39028887 · one of two readings recorded this

• Incidence of acute kidney injury (AKI)

  increases, p = 0.001, n = 147

  the incidence of AKI was higher in A+Z than in PRED, 45% (n= 33) vs. 22% (n= 16), p =0.001

  PMID:39028887 · one of two readings recorded this

• incidence of acute kidney injury by KDIGO criteria within 90 days, prednisone 40 mg orally once daily for 30 days versus anakinra plus zinc sulfate, severe alcohol-associated hepatitis

  AKI incidence 45% (n = 33) in anakinra plus zinc versus 22% (n = 16) in prednisone, p = 0.001

  Not recorded as a finding: the comparison was against another active treatment

  During the course of treatment, 33% (n= 49) developed AKI, and the incidence of AKI was higher in A+Z than in PRED, 45% (n= 33) vs. 22% (n= 16), p =0.001.

  PMID:39028887 · one of two readings recorded this

• Incidence of AKI, overall

  n = 147

  During the course of treatment, 33% (n= 49) developed AKI

  PMID:39028887 · one of two readings recorded this

• incident acute kidney injury by KDIGO serum creatinine criteria over 90 days, prednisone 40 mg daily versus anakinra plus zinc in severe alcohol-associated hepatitis

  AKI in 45% (n=33) of anakinra plus zinc versus 22% (n=16) of prednisone, p = 0.001, n = 147

  Not recorded as a finding: the comparison was against another active treatment

  During the course of treatment, 33% (n= 49) developed AKI, and the incidence of AKI was higher in A+Z than in PRED, 45% (n= 33) vs. 22% (n= 16), p =0.001.

  PMID:39028887 · one of two readings recorded this

• Incident AKI, multivariable competing risk analysis (A+Z vs PRED)

  increases, p = 0.005, n = 147

  only A+Z was independently associated with increased risk for AKI (subdistribution hazard ratio 2.35 [95% CI: 1.29, 4.27] p =0.005)

  PMID:39028887 · one of two readings recorded this

• Intravenous contrast 3 days before AKI onset

  no effect, p = 0.227

  received i.v. contrast (n =1/33 [3.0%] A+Z vs. n =2/16 [13.3%] PRED, p= 0.227)

  PMID:39028887 · one of two readings recorded this

• Log IL-1Ra level, AKI vs no AKI (A+Z arm)

  no effect, p = 0.771

  day 0 (3.8±1.9 AKI vs. 4.0±1.6 no-AKI, p=0.771)

  PMID:39028887 · one of two readings recorded this

• Log IL-1Ra level, AKI vs no AKI (A+Z arm)

  no effect, p = 0.242

  day 14 (6.7±3.5 AKI vs. 7.8±2.9 no-AKI, p=0.242)

  PMID:39028887 · one of two readings recorded this

• Log IL-1Ra level, AKI vs no AKI (A+Z arm)

  decreases, p = 0.01

  There was a difference in day 28 (2.7±1.1 AKI vs. 3.8±1.3 no-AKI, p=0.010)

  PMID:39028887 · one of two readings recorded this

• Log IL-1Ra level, AKI vs no AKI (A+Z arm)

  no effect, p = 0.182

  day 7 (8.4±3.0 AKI vs. 9.4±2.4 no-AKI, p=0.182)

  PMID:39028887 · one of two readings recorded this

• Mean serum creatinine on day 14, by arm and AKI status

  increases, p = 0.001

  2.5±2.7mg/dL (on A+Z and had AKI), 0.8±0.3mg/dL (on A+Z, did not have AKI), 1.2±0.7 mg/dL (on PRED and had AKI), and 0.7±0.2 mg/dL (on PRED, did not have AKI); p<0.001

  PMID:39028887 · one of two readings recorded this

• Mean serum creatinine on day 7, A+Z arm (with AKI vs without AKI)

  increases

  the mean sCr levels for those on A+Z were 1.5±0.9 mg/dL (with AKI) and 0.9±0.6 mg/dL (without AKI)

  PMID:39028887 · one of two readings recorded this

• Mean serum creatinine on day 7, PRED arm (with AKI vs without AKI)

  increases, p = 0.001

  for those on PRED, the mean values were 1.0±0.4 mg/dL (with AKI) and 0.7±0.2 mg/dL (without AKI); p<0.001

  PMID:39028887 · one of two readings recorded this

• Median albumin given in participants with AKI

  no effect, p = 0.582

  A+Z 100.0 [62.5, 127.5] g vs. PRED 118.8 [50.0, 200.0] g, p=0.582

  PMID:39028887 · one of two readings recorded this

• Median time from treatment start to AKI development

  no effect, p = 0.186

  The median (IQR) days of time from treatment start to AKI development was 10 days and did not differ between the 2 treatment arms (p = 0.186)

  PMID:39028887 · one of two readings recorded this

• Partial recovery from AKI

  no effect

  partial recovery was noted in 6/33 (18.2%) versus 3/16 (18.8%) on A+Z versus PRED respectively

  PMID:39028887 · one of two readings recorded this

• Participants who died with an AKI

  increases, p = 0.022

  the proportion of participants who died with an AKI was greater in the A+Z (14/74 [18.9%] than in the PRED group 4/73 [5.5%], p= 0.022

  PMID:39028887 · one of two readings recorded this

• Peak AKI stage 2

  increases

  peak stage 2 n=8/33 (24.2%) A+Z vs. n=1/16 (6.3%) PRED

  PMID:39028887 · one of two readings recorded this

• Peak AKI stage 3

  increases, p = 0.035

  peak stage 3 n=21/33 (63.6%) A+Z vs. n=8/16 (50.0%) PRED, p=0.035

  PMID:39028887 · one of two readings recorded this

• Progression of AKI

  6/16 (37.5%) and 13/33 (39.4%) participants in the PRED and A+Z arm experienced progression of AKI

  PMID:39028887 · one of two readings recorded this

• Renal replacement therapy among participants with AKI

  10/33 (30.3%) on A+Z versus 7/16 (43.8%) on PRED received RRT

  PMID:39028887 · one of two readings recorded this

• Treated for infection before AKI onset

  no effect, p = 0.703

  The proportion of participants being treated for infection was also similar in both treatment arms (n =6/33 [18.2%] A+Z vs. n= 4/16 [26.7%] PRED, p= 0.703)

  PMID:39028887 · one of two readings recorded this

• Urine KIM-1, AKI A+Z vs AKI PRED

  increases, p = 0.039

  1.5±0.9 vs. 0.2±2.1 ng/mL (p=0.039)

  PMID:39028887 · one of two readings recorded this

• Urine NGAL, AKI A+Z vs AKI PRED

  increases, p = 0.032

  5.0±1.3 vs. 3.1±1.4 ng/mL (p=0.002), 5.5±2.0 vs. 3.4±1.4 (p=0.032), and 4.5±0.9 vs. 2.6±1.2 (p=0.007)

  PMID:39028887 · one of two readings recorded this

• Urine NGAL, AKI A+Z vs AKI PRED

  increases, p = 0.007

  5.0±1.3 vs. 3.1±1.4 ng/mL (p=0.002), 5.5±2.0 vs. 3.4±1.4 (p=0.032), and 4.5±0.9 vs. 2.6±1.2 (p=0.007)

  PMID:39028887 · one of two readings recorded this

• Urine NGAL, AKI A+Z vs AKI PRED

  increases, p = 0.002

  5.0±1.3 vs. 3.1±1.4 ng/mL (p=0.002), 5.5±2.0 vs. 3.4±1.4 (p=0.032), and 4.5±0.9 vs. 2.6±1.2 (p=0.007)

  PMID:39028887 · one of two readings recorded this

• Adrenal suppression, peak cortisol <400 nmol/L

  Placebo | 589.9 (458, 750) [19] | 20.0% [4/20] | 0% [0/20]

  PMID:39097643 · one of two readings recorded this

• Adrenal suppression, peak cortisol <400 nmol/L

  increases

  Prednisone 0.75 mg/kg/day | 277.6 (138, 436) [25] | 100% [25/25] | 92.0% [23/25]

  PMID:39097643 · one of two readings recorded this

• Adrenal suppression, peak cortisol <400 nmol/L

  increases

  Vamorolone 2 mg/kg/day | 392.8 (193, 618) [19] | 84.2% [16/19] | 47.4% [9/19]

  PMID:39097643 · one of two readings recorded this

• Adrenal suppression, peak cortisol <400 nmol/L

  increases

  Vamorolone 6 mg/kg/day | 180.9 (11, 665) [21] | 95.2% [20/21] | 90.5% [19/21]

  PMID:39097643 · one of two readings recorded this

• Adrenal suppression, peak cortisol <500 nmol/L

  Placebo | 589.9 (458, 750) [19] | 20.0% [4/20] | 0% [0/20]

  PMID:39097643 · one of two readings recorded this

• Adrenal suppression, peak cortisol <500 nmol/L

  increases

  Prednisone 0.75 mg/kg/day | 277.6 (138, 436) [25] | 100% [25/25] | 92.0% [23/25]

  PMID:39097643 · one of two readings recorded this

The whole record — 377 rows